CHRS Coherus BioSciences Inc.

13.92
-0.02  -0%
Previous Close 13.94
Open 13.95
Price To Book 77.33
Market Cap 946907972
Shares 68,024,998
Volume 107,379
Short Ratio
Av. Daily Volume 719,616

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Rheumatoid arthritis
Phase 2b data released June 2016
CHS-131
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 top-line data met endpoints August 2016. BLA filing due late 2019.
CHS-1420
Psoriasis
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
FDA approval announced November 2, 2018.
CHS-1701
Pegfilgrastim biosimilar